Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Effects of Talampanel on Patients With Advanced Parkinson`s Disease

Study:

Effects of Talampanel on Patients With Advanced Parkinson`s Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)

Rationale:

n/a

Purpose:

The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson`s disease. It is not clear why people with Parkinson`s disease develop involuntary movements (dyskinesias) but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements. Talampanel is a drug which blocks these receptors.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Dyskinesias
Parkinson Disease
Movement Disorders
Drug: talampanel Phase 1/Phase 2

Verified by IVAX Research LLC March, 2008

Sponsored by: IVAX Research LLC
Information provided by: IVAX Research LLC
ClinicalTrials.gov identifier: NCT00036296

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Florida
Weston, Florida 33331
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site